Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof William Kemp

A/Prof William Kemp

Cardiovascular Risk and Fatty Liver Disease

Dr Ryan De Cruz

Dr Ryan De Cruz

Importance of Early & Effective Treatment of Mild to Moderate Acne

Prof Merlin Thomas

Prof Merlin Thomas

SGLT2s and Renal Protection

Dr Adam Nelson

Dr Adam Nelson

CV Medications – Practical Strategies to Improve Compliance

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022